GABA abnormalities in schizophrenia: A methodological review of in vivo studies

Schizophrenia Research

Volumn 167, Issue 1-3, 2015, Pages 84-90

  Taylor, Stephan F ^a   Tso, Ivy F ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

Benzodiazepine; FMRI; MRS; PET; Psychosis; TMS

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR; 4 AMINOBUTYRIC ACID; GABAERGIC RECEPTOR AFFECTING AGENT;

AUTOPSY; BRAIN REGION; COGNITIVE DEFECT; DISEASE ASSESSMENT; EMOTIONALITY; GABAERGIC SYSTEM; HUMAN; IN VIVO STUDY; MEDICAL LITERATURE; MOTOR ACTIVITY; NEUROIMAGING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN FUNCTION; RECEPTOR BINDING; REVIEW; SCHIZOPHRENIA; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TRANSCRANIAL MAGNETIC STIMULATION; ANIMAL; BRAIN; DRUG EFFECTS; INTERNEURON; METABOLISM; PATHOLOGY;

ANIMALS; BRAIN; GABA AGENTS; GAMMA-AMINOBUTYRIC ACID; HUMANS; INTERNEURONS; MAGNETIC RESONANCE SPECTROSCOPY; NEUROIMAGING; SCHIZOPHRENIA; TRANSCRANIAL MAGNETIC STIMULATION;

EID: 84942194011     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2014.10.011     Document Type: Review

References (105)

1. Abi-Dargham A., Laruelle M., Krystal J., D'Souza C., Zoghbi S., Baldwin R.M., Seibyl J., Mawlawi O., de Erasquin G., Charney D., Innis R.B. No evidence of altered in vivo benzodiazepine receptor binding in schizophrenia. Neuropsychopharmacology 1999, 20(6):650-661.
2. Ahn K., Gil R., Seibyl J., Sewell R.A., D'Souza D.C. Probing GABA receptor function in schizophrenia with iomazenil. Neuropsychopharmacology 2011, 36(3):677-683.
3. Akbarian S., Huang H.S. Molecular and cellular mechanisms of altered GAD1/GAD67 expression in schizophrenia and related disorders. Brain Res. Rev. 2006, 52(2):293-304.
4. Akbarian S., Kim J.J., Potkin S.G., Hagman J.O., Tafazzoli A., Bunney W.E., Jones E.G. Gene expression for glutamic acid decarboxylase is reduced without loss of neurons in prefrontal cortex of schizophrenics. Arch. Gen. Psychiatry 1995, 52:258-266.
5. Asai Y., Takano A., Ito H., Okubo Y., Matsuura M., Otsuka A., Takahashi H., Ando T., Ito S., Arakawa R., Asai K., Suhara T. GABAA/benzodiazepine receptor binding in patients with schizophrenia using [11C]Ro15-4513, a radioligand with relatively high affinity for alpha5 subunit. Schizophr. Res. 2008, 99(1-3):333-340.
6. Ball S., Busatto G.F., David A.S., Jones S.H., Hemsley D.R., Pilowsky L.S., Costa D.C., Ell P.J., Kerwin R.W. Cognitive functioning and GABAA/benzodiazepine receptor binding in schizophrenia: a 123I-iomazenil SPET study. Biol. Psychiatry 1998, 43(2):107-117.
7. Bartos M., Vida I., Jonas P. Synaptic mechanisms of synchronized gamma oscillations in inhibitory interneuron networks. Nature reviews. Neuroscience 2007, 8(1):45-56.
8. Beasley C.L., Zhang Z.J., Patten I., Reynolds G.P. Selective deficits in prefrontal cortical GABAergic neurons in schizophrenia defined by the presence of calcium-binding proteins. Biol. Psychiatry 2002, 52(7):708-715.
9. Benes F.M. Amygdalocortical circuitry in schizophrenia: from circuits to molecules. Neuropsychopharmacology 2010, 35(1):239-257.
10. Benes F.M., McSparren J., Bird E.D., SanGiovanni J.P., Vincent S.L. Deficits in small interneurons in prefrontal and cingulate cortices of schizophrenic and schizoaffective patients. Arch. Gen. Psychiatry 1991, 48(11):996-1001.
11. Benes F.M., Kwok E.W., Vincent S.L., Todtenkopf M.S. A reduction of nonpyramidal cells in sector CA2 of schizophrenics and manic depressives. Biol. Psychiatry 1998, 44(2):88-97.
12. Benes F.M., Lim B., Matzilevich D., Walsh J.P., Subburaju S., Minns M. Regulation of the GABA cell phenotype in hippocampus of schizophrenics and bipolars. Proc. Natl. Acad. Sci. U. S. A. 2007, 104(24):10164-10169.
13. Beneyto M., Abbott A., Hashimoto T., Lewis D.A. Lamina-specific alterations in cortical GABA(A) receptor subunit expression in schizophrenia. Cereb. Cortex 2011, 21(5):999-1011.
14. Brickley S.G., Mody I. Extrasynaptic GABA(A) receptors: their function in the CNS and implications for disease. Neuron 2012, 73(1):23-34.
15. Buchanan R.W., Keefe R.S., Lieberman J.A., Barch D.M., Csernansky J.G., Goff D.C., Gold J.M., Green M.F., Jarskog L.F., Javitt D.C., Kimhy D., Kraus M.S., McEvoy J.P., Mesholam-Gately R.I., Seidman L.J., Ball M.P., McMahon R.P., Kern R.S., Robinson J., Marder S.R. A randomized clinical trial of MK-0777 for the treatment of cognitive impairments in people with schizophrenia. Biol. Psychiatry 2011, 69(5):442-449.
16. Busatto G.F., Pilowsky L.S., Costa D.C., Ell P.J., David A.S., Lucey J.V., Kerwin R.W. Correlation between reduced in vivo benzodiazepine receptor binding and severity of psychotic symptoms in schizophrenia. Am. J. Psychiatry 1997, 154(1):56-63.
17. Buzsaki G., Draguhn A. Neuronal oscillations in cortical networks. Science 2004, 304(5679):1926-1929.
18. Carpenter W.T., Buchanan R.W., Kirkpatrick B., Breier A.F. Diazepam treatment of early signs of exacerbation in schizophrenia. Am. J. Psychiatry 1999, 156(2):299-303.
19. Chen C.M., Stanford A.D., Mao X., Abi-Dargham A., Shungu D.C., Lisanby S.H., Schroeder C.E., Kegeles L.S. GABA level, gamma oscillation, and working memory performance in schizophrenia. Neuroimage Clin. 2014, 4:531-539.
20. Coyle J.T. The GABA-glutamate connection in schizophrenia: which is the proximate cause?. Biochem. Pharmacol. 2004, 68(8):1507-1514.
21. Curley A.A., Arion D., Volk D.W., Asafu-Adjei J.K., Sampson A.R., Fish K.N., Lewis D.A. Cortical deficits of glutamic acid decarboxylase 67 expression in schizophrenia: clinical, protein, and cell type-specific features. Am. J. Psychiatry 2011, 168(9):921-929.
22. Daskalakis Z.J., Christensen B.K., Chen R., Fitzgerald P.B., Zipursky R.B., Kapur S. Evidence for impaired cortical inhibition in schizophrenia using transcranial magnetic stimulation. Arch. Gen. Psychiatry 2002, 59(4):347-354.
23. Daskalakis Z.J., Christensen B.K., Fitzgerald P.B., Moller B., Fountain S.I., Chen R. Increased cortical inhibition in persons with schizophrenia treated with clozapine. J. Psychopharmacol. 2008, 22(2):203-209.
24. Di Lazzaro V., Oliviero A., Meglio M., Cioni B., Tamburrini G., Tonali P., Rothwell J.C. Direct demonstration of the effect of lorazepam on the excitability of the human motor cortex. Clin. Neurophysiol. 2000, 111(5):794-799.
25. Di Lazzaro V., Pilato F., Dileone M., Ranieri F., Ricci V., Profice P., Bria P., Tonali P.A., Ziemann U. GABAA receptor subtype specific enhancement of inhibition in human motor cortex. J. Physiol. 2006, 575(Pt 3):721-726.
26. Eichhammer P., Wiegand R., Kharraz A., Langguth B., Binder H., Hajak G. Cortical excitability in neuroleptic-naive first-episode schizophrenic patients. Schizophr. Res. 2004, 67(2-3):253-259.
27. Ferrarelli F., Massimini M., Peterson M.J., Riedner B.A., Lazar M., Murphy M.J., Huber R., Rosanova M., Alexander A.L., Kalin N., Tononi G. Reduced evoked gamma oscillations in the frontal cortex in schizophrenia patients: a TMS/EEG study. Am. J. Psychiatry 2008, 165(8):996-1005.
28. Fitzgerald P.B., Brown T.L., Daskalakis Z.J., Kulkarni J. A transcranial magnetic stimulation study of inhibitory deficits in the motor cortex in patients with schizophrenia. Psychiatry Res. 2002, 114(1):11-22.
29. Fitzgerald P.B., Brown T.L., Daskalakis Z.J., Kulkarni J. A transcranial magnetic stimulation study of the effects of olanzapine and risperidone on motor cortical excitability in patients with schizophrenia. Psychopharmacology 2002, 162(1):74-81.
30. Fitzgerald P.B., Brown T.L., Marston N.A., Oxley T., De Castella A., Daskalakis Z.J., Kulkarni J. Reduced plastic brain responses in schizophrenia: a transcranial magnetic stimulation study. Schizophr. Res. 2004, 71(1):17-26.
31. Fries P., Reynolds J.H., Rorie A.E., Desimone R. Modulation of oscillatory neuronal synchronization by selective visual attention. Science 2001, 291(5508):1560-1563.
32. Fuchs E.C., Zivkovic A.R., Cunningham M.O., Middleton S., Lebeau F.E., Bannerman D.M., Rozov A., Whittington M.A., Traub R.D., Rawlins J.N., Monyer H. Recruitment of parvalbumin-positive interneurons determines hippocampal function and associated behavior. Neuron 2007, 53(4):591-604.
33. Gonzalez-Burgos G., Fish K.N., Lewis D.A. GABA neuron alterations, cortical circuit dysfunction and cognitive deficits in schizophrenia. Neural Plast. 2011, 2011:723184.
34. Goto N., Yoshimura R., Kakeda S., Moriya J., Hayashi K., Ikenouchi-Sugita A., Umene-Nakano W., Hori H., Ueda N., Korogi Y., Nakamura J. Associations between plasma levels of 3-methoxy-4-hydroxyphenylglycol (MHPG) and negative symptoms or cognitive impairments in early-stage schizophrenia. Hum. Psychopharmacol. 2009, 24(8):639-645.
35. Goto N., Yoshimura R., Moriya J., Kakeda S., Ueda N., Ikenouchi-Sugita A., Umene-Nakano W., Hayashi K., Oonari N., Korogi Y., Nakamura J. Reduction of brain gamma-aminobutyric acid (GABA) concentrations in early-stage schizophrenia patients: 3T Proton MRS study. Schizophr. Res. 2009, 112(1-3):192-193.
36. Gray C.M., Konig P., Engel A.K., Singer W. Oscillatory responses in cat visual cortex exhibit inter-columnar synchronization which reflects global stimulus properties. Nature 1989, 338(6213):334-337.
37. Guidotti A., Auta J., Davis J.M., Di-Giorgi-Gerevini V., Dwivedi Y., Grayson D.R., Impagnatiello F., Pandey G., Pesold C., Sharma R., Uzunov D., Costa E. Decrease in reelin and glutamic acid decarboxylase67 (GAD67) expression in schizophrenia and bipolar disorder: a postmortem brain study. Arch. Gen. Psychiatry 2000, 57(11):1061-1069.
38. Guidotti A., Auta J., Davis J.M., Dong E., Grayson D.R., Veldic M., Zhang X., Costa E. GABAergic dysfunction in schizophrenia: new treatment strategies on the horizon. Psychopharmacology (Berl.) 2005, 180(2):191-205.
39. Hasan A., Nitsche M.A., Rein B., Schneider-Axmann T., Guse B., Gruber O., Falkai P., Wobrock T. Dysfunctional long-term potentiation-like plasticity in schizophrenia revealed by transcranial direct current stimulation. Behav. Brain Res. 2011, 224(1):15-22.
40. Hasan A., Wobrock T., Grefkes C., Labusga M., Levold K., Schneider-Axmann T., Falkai P., Muller H., Klosterkotter J., Bechdolf A. Deficient inhibitory cortical networks in antipsychotic-naive subjects at risk of developing first-episode psychosis and first-episode schizophrenia patients: a cross-sectional study. Biol. Psychiatry 2012, 72(9):744-751.
41. Hashimoto T., Volk D.W., Eggan S.M., Mirnics K., Pierri J.N., Sun Z., Sampson A.R., Lewis D.A. Gene expression deficits in a subclass of GABA neurons in the prefrontal cortex of subjects with schizophrenia. J. Neurosci. 2003, 23(15):6315-6326.
42. Hashimoto T., Arion D., Unger T., Maldonado-Aviles J.G., Morris H.M., Volk D.W., Mirnics K., Lewis D.A. Alterations in GABA-related transcriptome in the dorsolateral prefrontal cortex of subjects with schizophrenia. Mol. Psychiatry 2008, 13(2):147-161.
43. Hashimoto T., Bazmi H.H., Mirnics K., Wu Q., Sampson A.R., Lewis D.A. Conserved regional patterns of GABA-related transcript expression in the neocortex of subjects with schizophrenia. Am. J. Psychiatry 2008, 165(4):479-489.
44. Holcomb H.H., Lahti A.C., Medoff D.R., Cullen T., Tamminga C.A. Effects of noncompetitive NMDA receptor blockade on anterior cingulate cerebral blood flow in volunteers with schizophrenia. Neuropsychopharmacology 2005, 30(12):2275-2282.
45. Homayoun H., Moghaddam B. NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons. J. Neurosci. 2007, 27(43):11496-11500.
46. Javitt D.C., Zukin S.R. Recent advances in the phencyclidine model of schizophrenia. Am. J. Psychiatry 1991, 148(10):1301-1308.
47. Kegeles L.S., Mao X., Stanford A.D., Girgis R., Ojeil N., Xu X., Gil R., Slifstein M., Abi-Dargham A., Lisanby S.H., Shungu D.C. Elevated prefrontal cortex gamma-aminobutyric acid and glutamate-glutamine levels in schizophrenia measured in vivo with proton magnetic resonance spectroscopy. Arch. Gen. Psychiatry 2012, 69(5):449-459.
48. Kelemen O., Kiss I., Benedek G., Keri S. Perceptual and cognitive effects of antipsychotics in first-episode schizophrenia: the potential impact of GABA concentration in the visual cortex. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2013, 47:13-19.
49. Kinney J.W., Davis C.N., Tabarean I., Conti B., Bartfai T., Behrens M.M. A specific role for NR2A-containing NMDA receptors in the maintenance of parvalbumin and GAD67 immunoreactivity in cultured interneurons. J. Neurosci. 2006, 26(5):1604-1615.
50. Knable M.B., Barci B.M., Webster M.J., Meador-Woodruff J., Torrey E.F. Molecular abnormalities of the hippocampus in severe psychiatric illness: postmortem findings from the Stanley Neuropathology Consortium. Mol. Psychiatry 2004, 9(6):609-620. (544).
51. Konradi C., Yang C.K., Zimmerman E.I., Lohmann K.M., Gresch P., Pantazopoulos H., Berretta S., Heckers S. Hippocampal interneurons are abnormal in schizophrenia. Schizophr. Res. 2011, 131(1-3):165-173.
52. Korpi E.R., Sinkkonen S.T. GABA(A) receptor subtypes as targets for neuropsychiatric drug development. Pharmacol. Ther. 2006, 109(1-2):12-32.
53. Krystal J.H., Karper L.P., Seibyl J.P., Freeman G.K., Delaney R., Bremner J.D., Heninger G.R., Bowers M.B., Charney D.S. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch. Gen. Psychiatry 1994, 51(3):199-214.
54. Kujirai T., Caramia M.D., Rothwell J.C., Day B.L., Thompson P.D., Ferbert A., Wroe S., Asselman P., Marsden C.D. Corticocortical inhibition in human motor cortex. J. Physiol. 1993, 471:501-519.
55. Lahti A.C., Holcomb H.H., Medoff D.R., Tamminga C.A. Ketamine activates psychosis and alters limbic blood flow in schizophrenia. Neuroreport 1995, 6(6):869-872.
56. Lahti A.C., Koffel B., LaPorte D., Tamminga C.A. Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology 1995, 13(1):9-19.
57. Lee J.S., Lee J.D., Park H.J., Oh M.K., Chun J.W., Kim S.J., Kim E., Kim J.J. Is the GABA system related to the social competence improvement effect of aripiprazole? An (18)F-fluoroflumazenil PET study. Psychiatry Investig. 2013, 10(1):75-80.
58. Lewis D.A., Cho R.Y., Carter C.S., Eklund K., Forster S., Kelly M.A., Montrose D. Subunit-selective modulation of GABA type A receptor neurotransmission and cognition in schizophrenia. Am. J. Psychiatry 2008, 165(12):1585-1593.
59. Lewis D.A., Curley A.A., Glausier J.R., Volk D.W. Cortical parvalbumin interneurons and cognitive dysfunction in schizophrenia. Trends Neurosci. 2012, 35(1):57-67.
60. Lisman J. Excitation, inhibition, local oscillations, or large-scale loops: what causes the symptoms of schizophrenia?. Curr. Opin. Neurobiol. 2012, 22(3):537-544.
61. Lisman J.E., Coyle J.T., Green R.W., Javitt D.C., Benes F.M., Heckers S., Grace A.A. Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia. Trends Neurosci. 2008, 31(5):234-242.
62. Liu S.K., Fitzgerald P.B., Daigle M., Chen R., Daskalakis Z.J. The relationship between cortical inhibition, antipsychotic treatment, and the symptoms of schizophrenia. Biol. Psychiatry 2009, 65(6):503-509.
63. Lodge D.J., Grace A.A. Hippocampal dysregulation of dopamine system function and the pathophysiology of schizophrenia. Trends Pharmacol. Sci. 2011, 32(9):507-513.
64. Marenco S., Savostyanova A.A., van der Veen J.W., Geramita M., Stern A., Barnett A.S., Kolachana B., Radulescu E., Zhang F., Callicott J.H., Straub R.E., Shen J., Weinberger D.R. Genetic modulation of GABA levels in the anterior cingulate cortex by GAD1 and COMT. Neuropsychopharmacology 2010, 35(8):1708-1717.
65. Marenco S., Geramita M., van der Veen J.W., Barnett A.S., Kolachana B., Shen J., Weinberger D.R., Law A.J. Genetic association of ErbB4 and human cortical GABA levels in vivo. J. Neurosci. 2011, 31(32):11628-11632.
66. Markram H., Toledo-Rodriguez M., Wang Y., Gupta A., Silberberg G., Wu C. Interneurons of the neocortical inhibitory system. Nature reviews. Neuroscience 2004, 5(10):793-807.
67. Menzies L., Ooi C., Kamath S., Suckling J., McKenna P., Fletcher P., Bullmore E., Stephenson C. Effects of gamma-aminobutyric acid-modulating drugs on working memory and brain function in patients with schizophrenia. Arch. Gen. Psychiatry 2007, 64(2):156-167.
68. Nakazawa K., Zsiros V., Jiang Z., Nakao K., Kolata S., Zhang S., Belforte J.E. GABAergic interneuron origin of schizophrenia pathophysiology. Neuropharmacology 2012, 62(3):1574-1583.
69. Olney J.W., Farber N.B. Glutamate receptor dysfunction and schizophrenia. Arch. Gen. Psychiatry 1995, 52(12):998-1007.
70. Ongur D., Prescot A.P., McCarthy J., Cohen B.M., Renshaw P.F. Elevated gamma-aminobutyric acid levels in chronic schizophrenia. Biol. Psychiatry 2010, 68(7):667-670.
71. Oxley T., Fitzgerald P.B., Brown T.L., de Castella A., Daskalakis Z.J., Kulkarni J. Repetitive transcranial magnetic stimulation reveals abnormal plastic response to premotor cortex stimulation in schizophrenia. Biol. Psychiatry 2004, 56(9):628-633.
72. Pascual-Leone A., Manoach D.S., Birnbaum R., Goff D.C. Motor cortical excitability in schizophrenia. Biol. Psychiatry 2002, 52(1):24-31.
73. Pierri J.N., Chaudry A.S., Woo T.U., Lewis D.A. Alterations in chandelier neuron axon terminals in the prefrontal cortex of schizophrenic subjects. Am. J. Psychiatry 1999, 156(11):1709-1719.
74. Radhu N., de Jesus D.R., Ravindran L.N., Zanjani A., Fitzgerald P.B., Daskalakis Z.J. A meta-analysis of cortical inhibition and excitability using transcranial magnetic stimulation in psychiatric disorders. Clin. Neurophysiol. 2013, 124(7):1309-1320.
75. Rowland L.M., Edden R.A., Kontson K., Zhu H., Barker P.B., Hong L.E. GABA predicts inhibition of frequency-specific oscillations in schizophrenia. J. Neuropsychiatry Clin. Neurosci. 2013, 25(1):83-87.
76. Rowland L.M., Kontson K., West J., Edden R.A., Zhu H., Wijtenburg S.A., Holcomb H.H., Barker P.B. In vivo measurements of glutamate, GABA, and NAAG in schizophrenia. Schizophr. Bull. 2013, 39(5):1096-1104.
77. Rudolph U., Knoflach F. Beyond classical benzodiazepines: novel therapeutic potential of GABAA receptor subtypes. Nat. Rev. Drug Discov. 2011, 10(9):685-697.
78. Rudolph U., Mohler H. GABAA receptor subtypes: therapeutic potential in Down syndrome, affective disorders, schizophrenia, and autism. Annu. Rev. Pharmacol. Toxicol. 2014, 54:483-507.
79. Schroder J., Bubeck B., Demisch S., Sauer H. Benzodiazepine receptor distribution and diazepam binding in schizophrenia: an exploratory study. Psychiatry Res. 1997, 68(2-3):125-131.
80. Simpson M.D., Slater P., Deakin J.F., Royston M.C., Skan W.J. Reduced GABA uptake sites in the temporal lobe in schizophrenia. Neurosci. Lett. 1989, 107(1-3):211-215.
81. Sohal V.S., Zhang F., Yizhar O., Deisseroth K. Parvalbumin neurons and gamma rhythms enhance cortical circuit performance. Nature 2009, 459(7247):698-702.
82. Stokes P.R., Myers J.F., Kalk N.J., Watson B.J., Erritzoe D., Wilson S.J., Cunningham V.J., Barros D.R., Hammers A., Turkheimer F.E., Nutt D.J., Lingford-Hughes A.R. Acute increases in synaptic GABA detectable in the living human brain: a [C]Ro15-4513 PET study. NeuroImage 2014, 99:158-165.
83. Strube W., Wobrock T., Bunse T., Palm U., Padberg F., Malchow B., Falkai P., Hasan A. Impairments in motor-cortical inhibitory networks across recent-onset and chronic schizophrenia: a cross-sectional TMS Study. Behav. Brain Res. 2014, 264:17-25.
84. Szabadics J., Varga C., Molnar G., Olah S., Barzo P., Tamas G. Excitatory effect of GABAergic axo-axonic cells in cortical microcircuits. Science 2006, 311(5758):233-235.
85. Takahashi S., Ukai S., Kose A., Hashimoto T., Iwatani J., Okumura M., Tsuji T., Shinosaki K. Reduction of cortical GABAergic inhibition correlates with working memory impairment in recent onset schizophrenia. Schizophr. Res. 2013, 146(1-3):238-243.
86. Tallon-Baudry C., Bertrand O., Peronnet F., Pernier J. Induced gamma-band activity during the delay of a visual short-term memory task in humans. J. Neurosci. 1998, 18(11):4244-4254.
87. Tan K.R., Rudolph U., Luscher C. Hooked on benzodiazepines: GABAA receptor subtypes and addiction. Trends Neurosci. 2011, 34(4):188-197.
88. Taylor S.F., Demeter E., Phan K.L., Tso I.F., Welsh R.C. Abnormal GABAergic function and negative affect in schizophrenia. Neuropsychopharmacology 2014, 39(4):1000-1008.
89. Tayoshi S., Nakataki M., Sumitani S., Taniguchi K., Shibuya-Tayoshi S., Numata S., Iga J., Ueno S., Harada M., Ohmori T. GABA concentration in schizophrenia patients and the effects of antipsychotic medication: a proton magnetic resonance spectroscopy study. Schizophr. Res. 2010, 117(1):83-91.
90. Torrey E.F., Barci B.M., Webster M.J., Bartko J.J., Meador-Woodruff J.H., Knable M.B. Neurochemical markers for schizophrenia, bipolar disorder, and major depression in postmortem brains. Biol. Psychiatry 2005, 57(3):252-260.
91. Uhlhaas P.J., Singer W. Abnormal neural oscillations and synchrony in schizophrenia. Nature reviews. Neuroscience 2010, 11(2):100-113.
92. Verhoeff N.P., Soares J.C., D'Souza C.D., Gil R., Degen K., Abi-Dargham A., Zoghbi S.S., Fujita M., Rajeevan N., Seibyl J.P., Krystal J.H., van Dyck C.H., Charney D.S., Innis R.B. [123I]Iomazenil SPECT benzodiazepine receptor imaging in schizophrenia. Psychiatry Res. 1999, 91(3):163-173.
93. Volk D.W., Pierri J.N., Fritschy J.M., Auh S., Sampson A.R., Lewis D.A. Reciprocal alterations in pre- and postsynaptic inhibitory markers at chandelier cell inputs to pyramidal neurons in schizophrenia. Cereb. Cortex 2002, 12(10):1063-1070.
94. Vollenweider F.X. Advances and pathophysiological models of hallucinogenic drug actions in humans: a preamble to schizophrenia research. Pharmacopsychiatry 1998, 31(Suppl. 2):92-103.
95. Wassef A.A., Dott S.G., Harris A., Brown A., O'Boyle M., Meyer W.J., Rose R.M. Critical review of GABA-ergic drugs in the treatment of schizophrenia. J. Clin. Psychopharmacol. 1999, 19(3):222-232.
96. Wobrock T., Schneider M., Kadovic D., Schneider-Axmann T., Ecker U.K., Retz W., Rosler M., Falkai P. Reduced cortical inhibition in first-episode schizophrenia. Schizophr. Res. 2008, 105(1-3):252-261.
97. Wobrock T., Hasan A., Malchow B., Wolff-Menzler C., Guse B., Lang N., Schneider-Axmann T., Ecker U.K., Falkai P. Increased cortical inhibition deficits in first-episode schizophrenia with comorbid cannabis abuse. Psychopharmacology 2010, 208(3):353-363.
98. Wolf D.H., Satterthwaite T.D., Loughead J., Pinkham A., Overton E., Elliott M.A., Dent G.W., Smith M.A., Gur R.C., Gur R.E. Amygdala abnormalities in first-degree relatives of individuals with schizophrenia unmasked by benzodiazepine challenge. Psychopharmacology 2011, 218(3):503-512.
99. Woo T.U., Miller J.L., Lewis D.A. Schizophrenia and the parvalbumin-containing class of cortical local circuit neurons. Am. J. Psychiatry 1997, 154(7):1013-1015.
100. Woo T.U., Walsh J.P., Benes F.M. Density of glutamic acid decarboxylase 67 messenger RNA-containing neurons that express the N-methyl-d-aspartate receptor subunit NR2A in the anterior cingulate cortex in schizophrenia and bipolar disorder. Arch. Gen. Psychiatry 2004, 61(7):649-657.
101. Woo T.U., Kim A.M., Viscidi E. Disease-specific alterations in glutamatergic neurotransmission on inhibitory interneurons in the prefrontal cortex in schizophrenia. Brain Res. 2008, 1218:267-277.
102. Woodruff A., Xu Q., Anderson S.A., Yuste R. Depolarizing effect of neocortical chandelier neurons. Front. Neural Circ. 2009, 3:15.
103. Yoon J.H., Maddock R.J., Rokem A., Silver M.A., Minzenberg M.J., Ragland J.D., Carter C.S. GABA concentration is reduced in visual cortex in schizophrenia and correlates with orientation-specific surround suppression. J. Neurosci. 2010, 30(10):3777-3781.
104. Zhang Y., Behrens M.M., Lisman J.E. Prolonged exposure to NMDAR antagonist suppresses inhibitory synaptic transmission in prefrontal cortex. J. Neurophysiol. 2008, 100(2):959-965.
105. Ziemann U. Pharmacology of TMS. Suppl. Clin. Neurophysiol. 2003, 56:226-231.